Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, is devoted to developing and commercializing novel therapeutics that treat respiratory, central nervous system and other disorders. The company's primary programs consist of a partial dopamine agonist, SLS-006, for patients with Parkinson's disease, an intranasal racemic ketamine, SLS-002, that treats suicidal ideation in patients with major depressive disorder, and SLS-005, a protein stabilizer that targets Sanfilippo syndrome and amyotrophic lateral sclerosis. Expanding their reach beyond these prototypes, Seelos also works on preclinical programs including a peptidic inhibitor, SLS-007, for Parkinson's patients, pediatric indications via SLS-008, H3 receptor antagonist SLS-010 and SLS-012. This ground-breaking company was estabilished in 2016, and its headquarters is located in New York, New York.